Huenges Katharina, Kolat Philipp, Panholzer Bernd, Haneya Assad
Department of Cardiovascular Surgery, University of Schleswig-Holstein Campus Kiel, Kiel, Germany.
Thorac Cardiovasc Surg Rep. 2021 Nov 10;10(1):e59-e60. doi: 10.1055/s-0041-1732344. eCollection 2021 Jan.
Posterior reversible encephalopathy syndrome (PRES) is a rare neurological disease possibly associated with the use of calcineurin inhibitors (CNI) like cyclosporine A. The case of a patient who developed severe PRES under CNI therapy shortly after heart transplantation is presented here. Cerebral computed tomography led to the diagnose of PRES in our patient. New therapy strategy with a quadruple immunosuppressive protocol (cortisone, mycophenolate mofetil, low-dose CNI, and a mechanistic target of rapamycin inhibitor) was started. Under the quadruple therapy, a neurologic recovery occurred. In PRES, the presented alternative therapy strategy may lead to improving neurological conditions and preserved transplant organ functions.
后部可逆性脑病综合征(PRES)是一种罕见的神经系统疾病,可能与使用环孢素A等钙调神经磷酸酶抑制剂(CNI)有关。本文介绍了一名心脏移植后不久在CNI治疗下发生严重PRES的患者病例。脑部计算机断层扫描确诊了我们患者的PRES。开始采用四联免疫抑制方案(皮质类固醇、霉酚酸酯、低剂量CNI和雷帕霉素作用靶点抑制剂)的新治疗策略。在四联疗法下,患者神经功能得以恢复。在PRES中,所提出的替代治疗策略可能会改善神经状况并保留移植器官功能。